Kras g12c

[DJL10]

i was diagnosed with stage IIIA nsclc Nov 2023. Im currently doing carboplatin/paclitaxel 7 rounds 1x weekly and 37 daily radiation treatment. I have been fortunate to not have any side effects other than severe acid reflux and fatigue. This past week found out i have BRCA2, and Kras g12c and STK11 mutations. Both mutations appear to be 2 more strikes against this disease. Anyone have these 2 mutations? Both appear to fight treatment. We intend to start immunotherapy for maintenance once my radiation is done.

[Denzie Moderator Volunteer]

Welcome to the Go2 for Lung Cancer Support page. Hopefully, someone will be checking in soon that has your biomarkers. I know there is a targeted therapy available as a second line of treatment for the KRAS mutation.

At this time there are several studies using trastuzumab which has proved to work well in HER2+ breast cancer as treatment for that biomarker in nsclc.

Sending hope that these are both available to you if you need them.

Also check out the KRAS Kickers on Facebook.

[JanetteR57]

I wouldn't say having those mutations represents 2 strikes against you - on the contrary - having known active mutations provides more options for targeted treatments. When I was diagnosed in January 2011, the only known target for which there were treatments then only on clinical trials were EGFR+ which I tested negative for.

In the intervening years as more targets/drivers have been discovered, more new treatments have been trialled and developed and many more as a result now have treatment options - i.e. more than one treatment mode available which is not always the case for those without such mutations. The UK last year approved sotorasib for KRAS G12c mutations and it had previously been thought that that mutation was 'undraggable' so always ask your clinician whether there are any other clinical trials offering treatments for you.

One of the problems in lung cancer which has had more treatments approved in the last 7 -8 years than in the previous 35 that many of the studies/trials have their own websites, are still gathering data before the treatments can be approved and tend not to appear when patients/public do a 'Dr Google search'.

I've been involved in lung cancer research since the end of 2013 and the treatment landscape has changed beyond recognition and continues to change. Many patients I've had the privilege of meeting were able to get on one treatment then when it stopped working, another had come along and that continues to be the case for many targets. Immunotherapy wasn't around at all for lung cancer when I was diagnosed.

Every other treatment mode, surgery, radiotherapy (including ablation), and chemotherapy bear little resemblance to the way treatments were delivered in 2011 whether the way they're delivered (UK now has majority keyhole rather than the open surgery I had) , radiotherapy very different in almost every treatment intention, chemotherapy different agents and now the majority of patients are offered multimodality treatment rather than single agent/mode.

KRAS Kickers group can probably offer you much more detail but never give up!

[Jenniferroseolson]

Hello, and welcome. Janette said so much of what I would have said to you as well. The options for lung cancer patients have increased tremendously since my diagnosis with Stage IV NSCLC in April 2015, nearly eight years ago. I don't have any actionable mutations but do have the KRAS g12d (and other notable) mutation. My first line was carboplatin plus pemetrexed. My fatigue was not as severe once I dropped the carboplatin, and those doublet treatments were really difficult for me. My second line, after targeted radiation to one site in my lungs, was Yervoy plus Opdivo. I remain on Opdivo every four weeks for maintenance. I did have a high MSH2 and moderate PDL1 expression which, if I understand correctly, increased the likelihood that I would respond well to the immunotherapy. At my initial biomarker testing in 2015, I had a lower PDL1 expression; changes can occur for better or worse over time, so you may need comprehensive biomarker testing more than once in the future if your cancer stops responding to a treatment. Keep an open mind about whether or not these mutations will make your cancer more or less likely to respond to your treatments. While some of us may share a mutation or cancer type, each of us is very unique and our bodies and cancers will respond in unique ways. There is hope! Best wishes, jennifer